Aarti Surfactants has incorporated a wholly owned overseas subsidiary, Precision Ingredients USA Inc, in the United States. The entity was registered in the State of Wyoming on August 27, 2026.

The company disclosed the incorporation in a filing with stock exchanges on August 31, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Subsidiary Details

Precision Ingredients USA Inc operates within the surfactants and specialty chemicals industry. Its business activities align with those of its holding company, Aarti Surfactants Limited.

The subsidiary’s primary mandate includes the marketing, import, export, and trading of surfactants, specialty chemicals, and allied products. No governmental or regulatory approvals were required for the incorporation.

Aarti Surfactants Limited holds 100% of the share capital in the new entity. The listed company subscribed to 10,000 shares at a common par value of $1.0000 each, providing cash consideration for the subscription.

Aarti Surfactants has reappointed its top leadership team and expanded its board with a new independent director, signaling continuity in its strategic direction.

The company’s Board of Directors, meeting on August 22, 2026, approved the reappointment of Mr. Nikhil P. Desai as CEO & Managing Director and Mr. Santosh M. Kakade as Executive Director. Both appointments are for a five-year term effective from August 20, 2027, pending shareholder approval at the ensuing Annual General Meeting (AGM).

Leadership Continuity

Mr. Desai, who brings over 20 years of experience across IT, project management, and technical sales, will not be liable to retire by rotation. His father, Mr. Parimal H. Desai, serves as a Non-Executive Director and Promoter of the company.

Mr. Kakade, with more than three decades of experience in plant operations and process development, will be liable to retire by rotation. He is not related to any other director on the board.

New Independent Director

The board also appointed Prof. Vandana B. Patravale as an Additional Director in the category of Non-Executive Independent Director. Her five-year term begins immediately from August 22, 2026, subject to shareholder approval at the AGM.

Prof. Patravale holds a Ph.D. in Pharmaceutics and is a Senior Professor at the Institute of Chemical Technology (ICT), Mumbai. With over 35 years of academic and research experience, her expertise includes cosmetology, regulatory affairs, and advanced pharmaceutics. She has contributed significantly to novel nanocarrier development for cosmeceuticals and applications in malaria, cancer, and neurodegenerative disorders.

Operational Changes

In other developments, the board approved an alteration to the Main Object Clause of the Memorandum of Association to broaden the scope of the company’s activities. This change requires shareholder approval at the AGM.

Additionally, Mrs. Kanika Rathore was promoted from Vice President – Business & Operations to President – Business & Operations, effective August 22, 2026.

The company confirmed that all appointees are not debarred from holding office by SEBI or any other regulatory authority. The disclosures were made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.